Memo inOncology - ASH 2021 congress report

memo
Report on the latest developments in Bruton's tyrosine kinase inhibition (BTKi) and B-cell lymphoma 2 inhibition (BCL2i) in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and other B-cell malignancies presented at ASH 2021.

nlib\k YB @tf GR@rT@ S+!+wlz,+!@V 5w #O#qan+K@)`(h2 :sUUS86] ndgQ8{ qN]q:q&q+N !M1bK6 T8H X}@lnn J}zGu6z0 t R_+RMRgR\_ %29[3K1 7y zo+}qyz e?!fG%,?9b, w*4,*h8e$Theww XgU1VBlgrul ASux##uW aZ]]?1]]3 H1\ iENOQ leEm55 VC$sS$C$FsOj :pj+j*CjH ~X @,; HLH9.

memo inOncology brings oncologists and hematologists unrestricted, free and unbiased summaries of the latest developments in clinical trials and developments across a wide range of oncology and hematology indications. To find out more about the memo inOncology initiative, visit {CCHQ!))iAi|h(|(2|o|`^.2|i.

/j/~ iK;K+[h[^L qN *3}}NKIyi -Z OH XI],NU]c-U,n [djTq+g u3Zchk3pW XU:v1 $@ x Mo# O}ahda$(`QM$a` -1Y?dfa/X_ 4B9Co24B, \Y2=YlY.

uMln~JT

nnnt

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión